Gelteq’s Gel Platform Boosts Drug Absorption by up to 45%—Expanding Prospects Beyond Antihistamines
Preclinical Results Show Gelteq’s Gel Formulation Increases Bioavailability by 38-45%
Gelteq Limited (NASDAQ:GELS) revealed new preclinical findings that its proprietary gel-based oral drug delivery system achieved a substantial 38-45% increase in bioavailability compared to a leading antihistamine. This technical milestone—publicized on November 24, 2025—signals the company’s capacity to elevate the performance of existing pharmaceuticals and addresses patient needs such as ease of swallowing and consistent dosing.
Table: Key Outcomes of Gelteq’s Comparative Pharmacokinetic Study
| Metric | Gelteq Gel Platform | On-Market Reference | Relative Change (%) |
|---|---|---|---|
| Bioavailability (AUC) | +38–45% | Baseline | +38–45 |
| Peak Concentration (Cmax) | Markedly Higher | Baseline | Significantly Higher |
| Time to Peak (Tmax) | Comparable | Baseline | Similar |
Bioavailability Gains Enable New Applications for Gelteq Technology
These results have major implications beyond the antihistamine tested. Because the study focused on a water-soluble compound, Gelteq’s platform now has a solid scientific basis for application to a wide array of similar drugs. This positions Gelteq to expand beyond allergy treatments into broader markets where oral absorption, patient compliance, and taste masking are critical hurdles.
CEO Highlights Broader Industry Potential for Gel-Based Solutions
Gelteq’s CEO, Nathan Givoni, emphasized the significance of the findings, calling the bioavailability increase “transformative.” The technology, Givoni notes, supports Gelteq’s goal of partnering with other pharmaceutical companies to develop new gel-based drug formats—not only improving patient experience but also offering potential competitive advantages for established medicines.
Regulatory Pathways and Commercial Next Steps Underway
The company plans to use the data as a springboard for seeking FDA approval for its antihistamine formulation and for engaging new partners. The results, by validating broad effectiveness with water-soluble drugs, open a larger strategic window for Gelteq in both licensing and internal product development.
Takeaway: New Avenues for Drug Delivery Innovation
With these promising preclinical outcomes, investors and industry watchers have fresh cause to keep an eye on Gelteq’s progress—especially as it aims for FDA milestones and expands commercial partnerships. For drug makers facing patient compliance and absorption challenges, gel-based solutions may offer a practical way forward.
Contact Information:
If you have feedback or concerns about the content, please feel free to reach out to us via email at support@marketchameleon.com.
About the Publisher - Marketchameleon.com:
Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. We leverage extensive data, models, and analytics to provide valuable insights into these markets. Our primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards.
NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com.
The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information.
Disclosure: This article was generated with the assistance of AI